EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression

Pancreatic cancer is one of the deadliest malignancies and effective treatment has always been lacking. In current study, we investigated how the type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) participates in the progression of pancreatic ductal adenocarcinoma (PDAC) for novel therapeutic potentials against this lethal disease. We found that PIPKIγ is up-regulated in all tested PDAC cell lines. The growth factor (including EGFR)-induced tyrosine phosphorylation of PIPKIγ is significantly elevated in in situ and metastatic PDAC tissues. Loss of PIPKIγ inhibits the aggressiveness of PDAC cells by restraining the activities of AKT and STAT3, as well as MT1-MMP expression. Therefore when planted into the pancreas of nude mice, PIPKIγ-depleted PDAC cells exhibits substantially repressed tumor growth and metastasis comparing to control PDAC cells. Results from further studies showed that the phosphorylation-deficient PIPKIγ mutant, unlike its wild-type counterpart, cannot rescue PDAC progression inhibited by PIPKIγ depletion. These findings indicate that PIPKIγ, functioning downstream of EGFR signaling, is critical to the progression of PDAC, and suggest that PIPKIγ is potentially a valuable therapeutic target for PDAC treatment.

[1]  Suyong Choi,et al.  Phosphatidylinositol Phosphate 5-Kinase Iγ and Phosphoinositide 3-Kinase/Akt Signaling Couple to Promote Oncogenic Growth* , 2015, Journal of Biological Chemistry.

[2]  Yue Sun,et al.  Prospects & Overviews Phosphatidylinositol 4,5-bisphosphate: Targeted Production and Signaling , 2022 .

[3]  L. Traub,et al.  Clathrin Regulates the Association of PIPKIγ661 with the AP-2 Adaptor β2 Appendage* , 2009, Journal of Biological Chemistry.

[4]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[5]  P. Philip,et al.  Targeting Epidermal Growth Factor Receptor–Related Signaling Pathways in Pancreatic Cancer , 2015, Pancreas.

[6]  Yue Sun,et al.  Type Iγ phosphatidylinositol phosphate kinase is required for EGF-stimulated directional cell migration , 2007, The Journal of cell biology.

[7]  M. Karin,et al.  The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. , 2011, Cancer Cell.

[8]  Stephen J. Weiss,et al.  Regulation of Cell Invasion and Morphogenesis in a Three-Dimensional Type I Collagen Matrix by Membrane-Type Matrix Metalloproteinases 1, 2, and 3 , 2000, The Journal of cell biology.

[9]  V. Haucke,et al.  Stimulation of phosphatidylinositol kinase type I-mediated phosphatidylinositol (4,5)-bisphosphate synthesis by AP-2μ–cargo complexes , 2006, Proceedings of the National Academy of Sciences.

[10]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[11]  Yue Sun,et al.  Movin' on up: the role of PtdIns(4,5)P(2) in cell migration. , 2006, Trends in cell biology.

[12]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[13]  N. Jamieson,et al.  Activation of the IL-6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resected Pancreatic Ductal Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.

[14]  Pietro De Camilli,et al.  Recruitment and regulation of phosphatidylinositol phosphate kinase type 1γ by the FERM domain of talin , 2002, Nature.

[15]  Alex J. Walsh,et al.  Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. , 2015, Gastroenterology.

[16]  D. Mosher,et al.  Tyrosine phosphorylation of type Iγ phosphatidylinositol phosphate kinase by Src regulates an integrin–talin switch , 2003, The Journal of cell biology.

[17]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[18]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[19]  J. Keski‐Oja,et al.  Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. , 1998, The Biochemical journal.

[20]  H. Sato,et al.  Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase. , 1996, Cancer research.

[21]  P. De Camilli,et al.  ARF6 stimulates clathrin/AP-2 recruitment to synaptic membranes by activating phosphatidylinositol phosphate kinase type Iγ , 2003, The Journal of cell biology.

[22]  Qingwen Xu,et al.  PIPKI&ggr; targets to the centrosome and restrains centriole duplication , 2014, Journal of Cell Science.

[23]  H. Fölsch.  Faculty Opinions recommendation of Type I gamma phosphatidylinositol phosphate kinase modulates adherens junction and E-cadherin trafficking via a direct interaction with mu 1B adaptin. , 2007 .

[24]  Wei Guo,et al.  Phosphatidylinositol 4,5-bisphosphate mediates the targeting of the exocyst to the plasma membrane for exocytosis in mammalian cells. , 2007, Molecular biology of the cell.

[25]  Y. Soini,et al.  Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[27]  K. Hirata,et al.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Grandis,et al.  STAT3 signaling: anticancer strategies and challenges. , 2011, Molecular interventions.

[29]  Delong Liu,et al.  Novel agents for advanced pancreatic cancer , 2015, Oncotarget.

[30]  F. Ciardiello,et al.  Targeting EGFR in pancreatic cancer treatment. , 2012, Current drug targets.

[31]  G. Sledge,et al.  Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells. , 1994, Life Science.

[32]  Suyong Choi,et al.  Isoform 5 of PIPKI&ggr; regulates the endosomal trafficking and degradation of E-cadherin , 2014, Journal of Cell Science.

[33]  H. Mori,et al.  CD44 directs membrane‐type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin‐like domain , 2002, The EMBO journal.

[34]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[35]  M. Fjällskog,et al.  Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  S. Leung,et al.  Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer , 2010, Breast Cancer Research.

[37]  Xiaojing Su,et al.  Type Iγ661 Phosphatidylinositol Phosphate Kinase Directly Interacts with AP2 and Regulates Endocytosis* , 2006, Journal of Biological Chemistry.

[38]  Xiaojun Tan,et al.  Endosomal type Iγ PIP 5-kinase controls EGF receptor lysosomal sorting. , 2013, Developmental cell.

[39]  J. Dagorn,et al.  A Review of Kinases Implicated in Pancreatic Cancer , 2010, Pancreatology.

[40]  K. Ling,et al.  Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions. , 2002, Nature.

[41]  M. Barbacid,et al.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[42]  S. Akira,et al.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.

[43]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[44]  R. Anderson,et al.  Two novel phosphatidylinositol-4-phosphate 5-kinase type Iγ splice variants expressed in human cells display distinctive cellular targeting , 2009, The Biochemical journal.

[45]  W. Rizwani,et al.  Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge , 2015, Cancers.

[46]  Motoharu Seiki,et al.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. , 2003, Cancer letters.